Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lonafarnib
Therapeutic Area : Genetic Disease
Study Phase : Approved
Recipient : Eiger BioPharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Sentynl Acquires Zokinvy® for Hutchinson-Gilford Progeria Syndrome
Details : Sentynl will commercialize Zokinvy (lonafarnib) globally, the first FDA-approved treatment targeting progeria symptoms.
Brand Name : Zokinvy
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 03, 2024
Lead Product(s) : Lonafarnib
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Recipient : Eiger BioPharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Fosdenopterin
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sentynl Receives MHRA Authorization for NULIBRY® in MoCD Type A
Details : Nulibry (fosdenopterin) is the first therapy for patients in Great Britain with molybdenum cofactor deficiency Type A, an ultra-rare genetic disorder that often progresses rapidly in infants.
Brand Name : Nulibry
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 16, 2024
Lead Product(s) : Fosdenopterin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
